Atuveciclib (Racemate)

Atuveciclib Racemate (BAY-1143572 Racemate) is the racemate mixture of Atuveciclib. Atuveciclib is a potent and highly selective, oral P-TEFb/CDK9 inhibitor which supresses CDK9/CycT1 with an IC50 of 13 nM.

Product Specifications

CAS Number

[1414943-88-6]

Product Name Alternative

BAY-1143572 (Racemate)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

CDK

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/BAY-1143572-Racemate.html

Concentration

10mM

Purity

98.48

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

N=S(CC1=CC(NC2=NC(C3=CC=C(F)C=C3OC)=NC=N2)=CC=C1)(C)=O

Molecular Formula

C18H18FN5O2S

Molecular Weight

387.43

Precautions

H302, H315, H319, H335

References & Citations

[1]Scholz A, et al. BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, shows convincing anti-tumor activity in preclinical models of acute myeloid leukemia (AML) . [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA) : AACR; Cancer Res 2016;76 (14 Suppl) :Abstract nr 3022.|[2]Scholz A, et al. BAY 1143572: A first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, inhibits MYC and shows convincing anti-tumor activity in multiple xenograft models by the induction of apoptosis. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA) : AACR; Cancer Res 2015;75 (15 Suppl) :Abstract nr DDT02-02. doi:10.1158/1538-7445.AM2015-DDT02-02